About
Nest Genomics builds an AI-native, HIPAA-compliant, lab-agnostic genetics platform that integrates with EHRs to identify at-risk patients, support testing workflows, provide clinical decision support, and manage longitudinal genomic care. It sells primarily to health systems and healthcare organizations, differentiating through modular end-to-end genomic workflows, broad lab compatibility, and deep EMR integration.
Market
Nest competes in provider-facing digital health and clinical-genomics software, particularly platforms that operationalize precision medicine and longitudinal genomic programs across health systems and clinics. It positions itself as an AI-native, lab-agnostic, EHR-integrated Genetics Copilot spanning patient identification, consent, ordering, results, clinical decision support, and ongoing management rather than a single diagnostic test or variant-interpretation tool. Its differentiation versus adjacent competitors is the claimed end-to-end workflow breadth, multi-lab flexibility, and integration with major EHR environments through SMART on FHIR and FHIR APIs.
Nest primarily targets mid-to-large health systems, multi-clinic provider organizations, and forward-thinking primary-care or specialty practices that want to launch or scale genomic and precision-medicine programs. Likely buyers and users include health-system leaders, clinical program owners, physicians, genetic counselors, and care teams; Nest reports use by more than 10 health systems and 50 U.S. clinics.
At a Glance
Problem
Nest Genomics addresses the operational gap between genetic testing and usable clinical care. Health systems and clinics often lack a scalable way to identify patients who meet testing criteria, educate and consent them, order through different laboratories, interpret results in the context of care, and manage follow-up over time. The pain is both clinical and economic: eligible high-risk patients can be missed, providers face added administrative work, and delayed results can postpone changes in management. The principal use case is proactively finding patients at risk for hereditary cancer, cardiovascular genetics, or other actionable conditions and moving them from screening through testing and lifelong care.
The economics are tied to finding more actionable patients while lowering the cost and friction of delivery. Nest’s own implementation calculator illustrates the potential with 560 high-risk patients identified, 1,100 patients with a change in management, and a modeled revenue opportunity of $1.392 million, although these are presented as calculator outputs rather than independently audited company-wide results.
Product / Service
Nest sells a lab-agnostic, EMR-integrated software platform—also described as the Nest Genetics Copilot—for health systems, clinics, pharmaceutical companies, and payors. Its AI-powered workflows use EMR and patient-reported data to surface eligible patients, then support risk assessment, education and consent, test ordering from a lab of choice, results ingestion and storage, provider clinical decision support, and longitudinal follow-up. The platform works through SMART on FHIR, FHIR APIs, and other data-exchange options, integrates with major EHRs including Epic and athenahealth, and connects to multiple laboratories.
The delivery model is modular: organizations can automate the end-to-end genomic-care journey or deploy only the capabilities they need. The intended benefit is to make precision medicine fit existing clinical workflows, expand access to genetic services, reduce operational burden, speed the path from referral to results, and help care teams act on findings. Nest’s partnership with Genome Medical extends the platform with genetic test ordering, medical consultations, and genetic counseling.
Market
Nest competes in genomic-care enablement and precision-medicine workflow software for healthcare organizations, rather than primarily as a genetic-testing laboratory. Its closest alternatives are a mixture of internal health-system workflows, lab-specific solutions, and adjacent population-genomics and clinical-genetics platforms. Helix is an adjacent competitor with clinical genomic testing and population-health programs, while Color offers provider-connected clinical management; Genome Medical is better characterized as a complementary service partner to Nest than as a direct competitor. The available evidence does not establish a definitive, authoritative list of direct competitors.
Nest appears to have moved beyond the pre-launch stage, although the evidence does not disclose revenue, profitability, or contract value. It was founded in 2022, entered Y Combinator’s Winter 2022 batch, raised an $8.5 million seed round in January 2023, and reported in October 2024 that it was used by more than 10 health systems and 50 U.S. clinics. Its athenahealth Marketplace availability, 2025 Genome Medical partnership, named health-system relationships, and a January 2026 company impact page reporting more than 24,666 patients impacted indicate active commercial and clinical deployment.
Founders & Leadership
Funding History
Y Combinator
B Capital
Recent News
Y Combinator’s 2026 genomics directory describes Nest as a lab-agnostic solution for organizations launching and implementing large-scale genomic programs.
Nest Genomics’s Impact page highlights its single platform for launching, coordinating, and scaling genomic programs, with genomic insights, orders, results, and clinical decision support integrated into the EHR.
MyOme and Ms.Medicine announced a strategic genomics partnership. The announcement states that MyOme tests are available through an existing partnership with Nest Genomics, whose platform integrates genomic insights into clinical workflows.
Epic’s showroom listed Nest Genomics as a SMART on FHIR solution and described its platform as improving healthcare outcomes, increasing access to genetic information, and scaling genetic services.
Active Roles
1Business Model
Nest Genomics operates as a B2B healthcare software company selling its genomic-care platform to health systems and other healthcare organizations, with distribution also supported through EHR marketplaces such as athenahealth. The available evidence does not disclose whether customers are charged by subscription, implementation, usage, or another specific pricing structure.